Current Report Filing (8-k)
September 12 2017 - 4:12PM
Edgar (US Regulatory)
United
States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 6, 2017
CHINA PHARMA
HOLDINGS, INC.
(Exact name of Registrant
as specified in charter)
Nevada
|
|
001-34471
|
|
73-1564807
|
(State or other jurisdiction
|
|
(Commission File No.)
|
|
(IRS Employer
|
of Incorporation)
|
|
|
|
Identification No.)
|
Second Floor, No. 17, Jinpan Road
Haikou, Hainan Province, China 570216
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including
area code:
+86 898-6681-1730 (China)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications
pursuant to Rule 425 under the Securities Act (17CFR230.425)
☐ Soliciting material pursuant
to Rule14a-12 under the Exchange Act (17CFR240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.01. Notice of Delisting or Failure
to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On September 6, 2017, China Pharma Holdings,
Inc. (the “Company”) received notification (the “Deficiency Letter”) from the NYSE AMERICAN LLC (“NYSE
American”) that it is not in compliance with certain NYSE American continued listing standards (the “Listing Standards”).
The Deficiency Letter indicated that the
Company’s securities have been selling for a low price per share for a substantial period of time and most recently the average
price of the Company’s common stock had been below $0.20 on a 30-day average price as of September 5, 2017. Pursuant to Section
1003(f)(v) of the NYSE American Company Guide, the NYSE American staff determined that the Company’s continued listing is
predicated on it effecting a reverse stock split of its common stock or otherwise demonstrating sustained price improvement within
a reasonable period of time, which the staff determined to be until March 6, 2018. The Company intends to regain compliance with
the Listing Standards by undertaking a measure or measures that are for the best interests of the Company and its shareholders.
The Company’s common stock will continue
to be listed on the NYSE American while it attempts to regain compliance with the Listing Standards, subject to the Company’s
compliance with other continued listing requirements. The NYSE American notification does not affect the Company’s business
operations or its reporting obligations under the Securities and Exchange Commission regulations and rules and does not conflict
with or cause an event of default under any of the Company’s material agreements.
The Company issued a press release on the
same day of this report announcing that it had received the Deficiency Letter. A copy of the press release is attached hereto as
Exhibit 99.1.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
The following is filed as an exhibit to this
report:
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: September 12, 2017
|
CHINA PHARMA HOLDINGS, INC.
|
|
|
|
By:
|
/s/ Zhilin Li
|
|
Name:
|
Zhilin Li
|
|
Title:
|
President and Chief Executive Officer
|
3
China Pharma (AMEX:CPHI)
Historical Stock Chart
From Mar 2024 to Apr 2024
China Pharma (AMEX:CPHI)
Historical Stock Chart
From Apr 2023 to Apr 2024